Clinical trials: B Acute Lymphoblastic Leukemia/Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Acute Lymphocytic Leukemia
A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LCAR-AIO, a triple-targeted cell preparation targeting CD19/CD20/CD22, in patients with relapsed/refractory B-cell acute lymphocytic…
- Trial name
- NCT05292898
- Testing
- LCAR-AIO Cells
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Nonmyeloablative Allogeneic Transplant
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a…
- Conditions
- Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- Mini-allo (NCT01272817)
- Testing
- Nonmyeloablative Allogeneic Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Scripps Health
Lymphoma
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00040950
- Testing
- rituximab, agatolimod sodium
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
B-cell Acute Lymphoblastic Leukemia
Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL
This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric…
- Trial name
- NCT06080191
- Testing
- CD19-CAR_Lenti_ALLO
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Hematologic Diseases, Hematologic Malignancy
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral…
- Conditions
- Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- 2019-KOE-001 (NCT04282174)
- Testing
- CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baptist Health South Florida
Lymphoma, Small Intestine Cancer
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00088868
- Testing
- alvespimycin hydrochloride
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Leukemia, Lymphoma
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating patients who have non-Hodgkin's lymphoma or…
- Trial name
- NCT00024115
- Testing
- BL22 immunotoxin, antibody therapy, biological response modifier therapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hematological Malignancies
Study of IV CBL0137 in Previously Treated Hematological Subjects
This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation (Part 1) and cohort-expansion study (Part 2) evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of intravenously (IV)…
- Trial name
- NCT02931110
- Testing
- CBL0137
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incuron
Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse
Coproporphyrine Isomers and Methotrexate Elimination
High dose methotrexate (MTX) is responsible of severe toxicity in patients in whom elimination from plasma is delayed. Factors responsible for MTX accumulation are partly known but some patients still experience toxicity despite…
- Conditions
- Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma
- Trial name
- COMETH (NCT00822432)
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Leukemia, Lymphoma
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00436618
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 277 people
- Sponsor
- Mayo Clinic
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Anemia, Chronic Myeloproliferative Disorders
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00301912
- Testing
- filgrastim, busulfan, fludarabine phosphate
- Where
- United States
- Sponsor
- University of California, San Francisco
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia
CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia
Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric…
- Trial name
- NCT06027957
- Testing
- anti-CD19 CAR T-cells
- Where
- Vietnam
- Volunteers
- 18 people
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.
- Trial name
- NCT02013167
- Testing
- Blinatumomab, Standard of Care Chemotherapy
- Where
- 117 sites in United States, Australia and 19 more
- Volunteers
- 405 people
- Sponsor
- Amgen
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
- Trial name
- PALL (NCT02808442)
- Testing
- UCART19
- Where
- 6 sites in United States, France and 2 more
- Volunteers
- 13 people
- Sponsor
- Institut de Recherches Internationales Servier
Leukemia, Lymphoma
Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)
The goal of this clinical research study is to learn if bendamustine can help to control Acute Lymphoblastic Leukemia/Lymphoma (ALL). The safety of this drug will also be studied.
- Trial name
- NCT01649622
- Testing
- Bendamustine
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.